MedTrace Logo

Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)

NCT04615845 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-01-03

No results posted yet for this study

Summary

This Phase 1 study to evaluate the safety of cancer immunotherapy with autologous dendritic cells(DC) in patients with metastatic castration resistant prostate cancer (mCRPC)

Conditions

  • Castration Resistant Prostate Cancer, CRPC

Interventions

BIOLOGICAL

Cellgram-DC-PC

Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes

Sponsors & Collaborators

  • Pharmicell Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • BUMJIN LIM, Ph.D · Asan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
79 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-21
Primary Completion
2022-02-15
Completion
2022-02-15

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04615845 on ClinicalTrials.gov